Journal or Book Title
Clinical Pharmacology and Therapeutics
The demonstration of bioequivalence (BE) is an essential requirement for ensuring that patients receive a product that performs as indicated by the label. The BE standard for a particular product is set by its innovator, and this standard must subsequently be matched by generic drug products. The Biopharmaceutics Classification System (BCS) sets a scientific basis for an improved BE standard for immediate-release solid oral dosage forms. In this paper, we discuss BE and the BCS, as well as the issues that are currently relevant to BE as a pharmaceutical product standard.
Works produced by employees of the U.S. Government as part of their official duties are not copyrighted within the U.S. The content of this document is not copyrighted.
Amidon, Kevin S.; Langguth, P.; Lennernas, H.; Yu, L.; and Amidon, G.L., "Bioequivalence of Oral Products and the Biopharmaceutics Classification System: Science, Regulation, and Public Policy" (2011). World Languages and Cultures Publications. 85.